Contact Us

Why GATC Health

Unlocking capital

Biotech executives face two primary challenges, attracting capital and spending it wisely. While scientists hotwire biology, combining data and science to push the boundaries of what medicine can achieve, leadership must overcome the fundamental hurdles of success.

GATC Health’s Derisq™ AI report provides the confidence executives, boards and investors require to take the next step—whether that’s closing the current round or green-lighting the spend on your next trial. Learn how this next step starts with your first step: Derisq.

Collaborate to innovate

Every day, biotech companies take the complexity and risks of drug development in their stride, creating possibilities for improved human health. What’s needed isn’t vision, it’s foresight. With a partner like GATC Health, you can leverage Operon’s™ groundbreaking AI-driven technology, to simulate human biology and predict drug candidate safety, efficacy and side effects.

Pipeline prioritization

Drug development is capital-intensive, which is why you need to be sure of that investment. Identify your most safe and effective candidates early on and reduce the likelihood of costly errors later in clinical trial.

Creating new IP

Operon can quickly and cost-effectively extend IP portfolios by identifying combination therapies and new indications. Or perhaps your research could be the basis for a collaborative blockbuster. GATC Health can add exponential value from discovery to patents’ end.

Setting a new pace

Timelines can be detrimentally slow in drug development. Discover new ways to save time and cut costs by using our AI platform.

Clinical success – not survival

We understand that your business is only as strong as its assets. De-risk your molecules before trial and increase the probability of their success.

Accurate predictions to revolutionize your discovery

Look ahead to the future with our Operon platform and be first to discover detailed, AI-driven analysis on each drug compound, specific to clinical trial endpoints, so you can be clear and confident on likely trial results far in advance.

Drug screening capabilities optimized 11 times above current industry standards

GATC Health’s AI-powered screening is two-fold, measuring in terms of both specificity and sensitivity. Specificity screening enables predictions for negative activation on biological targets, which is key in assessing the safety and side-effects of the molecule, while sensitivity screening conversely looks for positive activation to establish the efficacy of the molecule and perform a secondary assessment of safety and outcomes.  

With a rate of 86% true positives in sensitivity screening and 91% true negatives in specificity, our Operon platform affords biotech companies unmatched accuracy and highly reliable predictions to help steer decision-making early. 

Critical blind spots identified in early-stage development

A secondary indication. An adverse reaction. A side effect. With the Operon platform, you’re no longer in the dark about what could unfold in clinical trial. Leverage our AI to simulate trial outcomes, spot risk factors, and validate assumptions, all before a single patient is enrolled. 

Improved trial efficacy and clinical planning

By uncovering underlying side-effect mechanisms, potential trial dropout rates can be reduced, while predictive insights can enable a more targeted and meticulous patient selection strategy, boosting the probability of success.  

Take the first step: de-risk decision-making before clinical commitments

With AI fast becoming a required biotech tool and companies facing unprecedented financial constraints, tackle both at once with our Derisq AI report. Its deep multiomic insight allows you to save time and predict clinical outcomes, adverse effects and secondary indications, all ahead of clinical trial.

Operon platform

Operon platform

Your ambition wants a partner

Operon models human system biology to answer the most difficult human health questions. From de novo discovery and in silico research through each clinical phase, GATC Health is by your side for the win.

Find Out More
Derisq

Derisq

Confidence and capital efficiency

Mitigate clinical risk and pursue non-dilutive capital options, equipped with the key information you need to make the right decisions about your drug candidates.

Find Out More

Research & Publications

Amplifying your ingenuity with AI-powered analysis

GATC Health’s AI drug screening capabilities provide custom insights to help you shape discovery and development and reduce time to trial from years to months. Get started today.  

Contact us